RHHBY - Weight-Loss Drug Gold Rush Gets Larger As New Player Fractyl Health Files For $100M IPO | Benzinga
Fractyl Health, developing procedural and gene therapies for type 2 diabetes and obesity, filed an S-1 filing with the SEC on Thursday to raise up to $100 million in an initial public offering.
Fractyl Health is a metabolic therapeutics company focused on new approaches for metabolic diseases, including type 2 diabetes and obesity.
Its lead candidate, the Revita DMR System, is an outpatient procedural therapy designed to modify duodenal dysfunction.
Revita is approved for patients with inadequately controlled type 2 diabetes in Europe.
The company is enrolling a pivotal study of Revita ...